Indivior Pharmaceuticals Inc (INDV) — Fair Value Analysis

Base-case fair value (P50): $34.80 · Current price: $40.23 · Verdict: Fairly Valued

The Verdict on INDV

Our Monte Carlo simulations indicate that INDIVIOR PHARMACEUTICALS INC (INDV) is Fairly Valued at its current market price of $40.23. The probabilistic fair value assessment yields a median (P50) target of $34.80, suggesting a potential -13.5% gap relative to today's trading levels. This outcome positions INDV squarely within a balanced valuation zone, implying that the market is currently pricing in a reasonable expectation of its future financial performance and operational health.

How INDV stacks up against peers

Despite its sector being listed as n/a, our analysis of INDV's operational and financial health places it in an average quality tier. This assessment considers various fundamental metrics, helping to contextualize the fair value derived from our simulations. While the stock trades at $40.23, its average quality tier suggests it maintains competitive standing without exhibiting significant overperformance or underperformance in core business strength compared to market expectations. The $34.80 median fair value reflects this balanced quality profile.

What this means for investors

Investors considering INDV at $40.23 should note the Fairly Valued verdict and the $34.80 median fair value. The -13.5% difference against the current price reinforces that, based on thousands of simulated forward scenarios, the stock is neither significantly undervalued nor overvalued. While there isn't a substantial immediate upside indicated by the median fair value, an average quality tier implies a stable operational foundation. For a comprehensive understanding of potential downside scenarios or a more optimistic bull case, consider a FairCurve account to see the full probabilistic distribution and track INDV's fair value as new fundamentals are released.